T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication

Cytokine-related toxicity associated with the use of highly active chimeric antigen receptor T cells (CAR-T cells) is a significant clinical problem. By fusing the natural killer group 2D (NKG2D) ectodomain to 4-1BB and the DAP12 cytoplasmic domain containing only one immunoreceptor tyrosine-based activation motif, we have developed a 2nd-generation (2nd-Gen) NKG2D CAR for stable expression in human T cells. When compared to T cells modified with NKG2D CAR containing the commonly used CD3 zeta activation domain, T cells expressing the NKG2D-DAP12 CAR stimulated lower level release of interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), and interleukin (IL)-2 during tumor cell lysis and their proliferative activity was lower upon repeated antigen stimulation, although no difference between the two CARs was observed in mediating in vitro tumor cell lysis. In tumor-bearing NSG mice, both types of CAR-T cells displayed similar anti-tumor activity, being able to completely eradicate established solid tumor xenografts. However, treatment with the NKG2D-CDg CAR-T cells led to the death of most mice from xenogeneic graft versus host disease starting 30 days post-CAR-T cell injection, which was associated with a higher level of cytokine release, whereas all the mice treated with the NKG2D-DAP12 CAR-T cells survived well. Thus, the incorporation of the DAP12 activation domain in a CAR design may possibly provide a potential clinical advantage in mitigating the risk of cytokine release syndrome (CRS).

Automated summary

The study shows that T cells expressing NKG2D-DAP12 CAR have lower cytokine release during tumor cell lysis compared to those expressing the commonly used CD3 zeta activation domain, although there is no difference in mediating in vitro tumor cell lysis between the two CARs. Additionally, both types of CAR-T cells exhibit similar anti-tumor activity in tumor-bearing NSG mice, but NKG2D-CDg CAR-T cells lead to higher cytokine release and mortality due to xenogeneic graft versus host disease compared to NKG2D-DAP12 CAR-T cells. Incorporating the DAP12 activation domain in CAR design may provide a potential clinical advantage in mitigating the risk of cytokine release syndrome.